Fampridine approved for NHS use to aid walking in up to 5,000 MS patients

Fampridine, a prescription drug approved for people with multiple sclerosis (MS), works by enhancing nerve signal conduction in the spinal cord, which can improve walking speed and endurance. The medication is taken orally and is specifically indicated for patients who experience gait difficulties due to demyelination of nerve fibers.

Recent data indicate that roughly 5,000 individuals in the United States meet the criteria for fampridine therapy. Eligibility is determined by a confirmed diagnosis of MS, a measurable walking impairment, and the absence of certain contraindications such as severe kidney disease or a history of seizures. Clinicians assess each patient’s risk–benefit profile before initiating treatment, and ongoing monitoring is recommended to manage potential side effects.

The availability of fampridine offers a targeted option for MS patients seeking to regain mobility and independence. While it does not alter the underlying disease process, its ability to restore nerve function can translate into meaningful improvements in daily activities for those who qualify.